On August 19, Halis Kaan Akturk, MD of the Barbara Davis Center for Diabetes at University of Colorado and Alexis M. McKee, MD of the Division of Endocrinology, Metabolism and Lipid Research at Washington University School of Medicine, had their review titled “Emerging Technologies and Therapeutics for Type 1 Diabetes,” published online by Science Direct. […]
On May 4, Nathaniel Hogrebe, PhD; Matthew Ishahak, PhD; and Jeffrey Millman, PhD had their review titled “Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes,” published in Cell Stem Cell. In diabetes treatment, there is great potential for islet-like endocrine clusters from human pluripotent stem cells (hPSCs) to provide a limitless […]
Dr. Jeffrey Millman has received a renewal of his NIH R01 grant titled “Studying the Role of the Microenvironment on Differentiation and Maturation of Beta Cells”, providing 4 years of additional support into his research. Human pluripotent stem cells (hPSCs) hold great potential as a renewable source of insulin-producing islets for diabetes treatment. While transplantation […]
On May 2, Punn Augsornworawat, PhD received the Biomedical Engineering Outstanding Research Award for his work in the single-cell sequencing of stem cell-derived islets for diabetes cell therapy. Augsornworawat joined the Millman Lab back in 2018 as a doctoral student in the Biomedical Engineering PhD program. His interests lie in using bioinformatics to study islet development […]
On March 16, Jeffrey R. Millman, PhD and collaborators had their research titled “Differential Function and Maturation of Human Stem Cell-Derived Islets After Transplantation,” published in issue 3 of “Stem Cells Translational Medicine.” It is evident that cell replacement therapy is a potential treatment for patients with diabetes. One possible renewable source of replacement cells are stem-cell […]
On April 1, ReachMD released an interview featuring Alexis McKee, MD in their “Diabetes Discourse” series. The discussion is titled, “Collaborative Goal Setting in Type 2 Diabetes: Tailoring Treatment Plans for Patients.” In the 10-minute interview, McKee discusses communication strategies that can be used to create personalized treatment plans and to improve adherence among patients […]
Kim A. Carmichael, MD published a recent article in the February 2022 issue of Consultant 360 titled, “What Do You Need to Know About GLP-1 Receptors Agonists?” GLP-1 agonists, otherwise known as glucagon-like peptide 1 agonists, are an important class of medications for patients diagnosed with type 2 diabetes. As the author and series editor, […]